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ABSTRACT
Background Atypical teratoid/rhabdoid tumors (AT/RT) 
are highly aggressive CNS tumors of infancy and early 
childhood. Hallmark is the surprisingly simple genome 
with inactivating mutations or deletions in the SMARCB1 
gene as the oncogenic driver. Nevertheless, AT/RTs are 
infiltrated by immune cells and even clonally expanded T 
cells. However, it is unclear which epitopes T cells might 
recognize on AT/RT cells.
Methods Here, we report a comprehensive mass 
spectrometry (MS)- based analysis of naturally presented 
human leukocyte antigen (HLA) class I and class II ligands 
on 23 AT/RTs. MS data were validated by matching with 
a human proteome dataset and exclusion of peptides that 
are part of the human benignome. Cryptic peptide ligands 
were identified using Peptide- PRISM.
Results Comparative HLA ligandome analysis of the 
HLA ligandome revealed 55 class I and 139 class II 
tumor- exclusive peptides. No peptide originated from the 
SMARCB1 region. In addition, 61 HLA class I tumor- exclusive 
peptide sequences derived from non- canonically translated 
proteins. Combination of peptides from natural and cryptic 
class I and class II origin gave optimal representation of 
tumor cell compartments. Substantial overlap existed with 
the cryptic immunopeptidome of glioblastomas, but no 
concordance was found with extracranial tumors. More than 
80% of AT/RT exclusive peptides were able to successfully 
prime CD8+ T cells, whereas naturally occurring memory 
responses in AT/RT patients could only be detected for class 
II epitopes. Interestingly, >50% of AT/RT exclusive class II 
ligands were also recognized by T cells from glioblastoma 
patients but not from healthy donors.
Conclusions These findings highlight that AT/RTs, 
potentially paradigmatic for other pediatric tumors 
with a low mutational load, present a variety of highly 
immunogenic HLA class I and class II peptides from 
canonical as well as non- canonical protein sources. 
Inclusion of such cryptic peptides into therapeutic vaccines 
would enable an optimized mapping of the tumor cell 
surface, thereby reducing the likelihood of immune evasion.
BACKGROUND
Atypical teratoid/rhabdoid tumors (AT/
RTs) are malignant tumors of infancy and 
early childhood. They represent 50% of 
brain tumors in children under 1 year. 
Despite multimodal therapy, consisting of 
neurosurgery, polychemotherapy and, when-
ever possible in these small children, radio-
therapy, 5- year event- free survival is only 
30%.1 One hallmark of this cancer are the 
surprisingly simple genomes, the oncogenic 
driver is usually restricted to a homozoy-
gous deletional mutation in the SMARCB1 
gene.2 More recently, AT/RTs have been 
categorized into the TYR, SHH, and MYC 
subgroups, which display distinct molecular 
and clinical features.3 4 In cancer mutation 
rankings, AT/RTs are frequently considered 
the human cancer with the lowest mutational 
load.5 Although tumor mutational burden 
has emerged as an important biomarker for 
response to immunotherapy in certain adult 
cancer,6 this parameter is far from being 
exclusive. Immunohistological studies have 
revealed that AT/RTs can contain consider-
able infiltrations of immune cells including 
T cells.7 More recent RNA- seq data suggested 
that in the SHH- and MYC subgroups of AT/
RTs macrophages play an important role in 
tumor cell progression8 and that these two 
subgroups also contain gene signatures of 
clonally expanded CD4+ and CD8+ T cells.9 10 
Attempts to categorize immune cell infiltrates 
by DNA methylation data identified three 
immune microenvironment clusters, but 
no clear difference between immune cells 
in AT/RT subtypes.11 Finally, tumor- specific 
CD8+ T cell responses were reported in a 
small case series of AT/RT patients receiving 
tumor- specific therapeutic vaccines.12 These 
data provide indications that from an immu-
nological perspective, this tumor entity may 
not be entirely cold. However, the targets of 
a possible T cell recognition are unknown so 
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far. To address this issue, we performed a comprehen-
sive analysis of AT/RT specific T cell epitope candidates. 
Due to the extremely low mutational load in AT/RTs, we 
considered neoantigens derived from non- synonymous 
mutations as an unlikely source of candidate peptides 
and therefore focused our investigation on peptides 
eluted from human leukocyte antigen (HLA) class I and 
II molecules of primary tumor tissue. Our intention was 
to develop a strategy for vaccine design in low mutational 
tumors in which a maximal representation of the entire 
ligandome of the tumor cell is given, thereby preventing 
immune escape. Thus, our mass spectrometry (MS)- based 
discovery workflow and downstream computational anal-
ysis took into account tumor- associated antigens derived 
from canonical non- mutated or overexpressed natural 
proteins and antigens from non- canonical or cryptic 
sequences, which have recently been reported to account 
for up to 15% of the immunopeptidome.13 14 Our data 
demonstrate that AT/RTs express a plethora of tumor- 
specific and immunogenic HLA class I and class II ligands 
from highly diverse origin. Cryptic peptides represent a 
hitherto untapped source of potential T cell epitopes 
that should be considered for personalized tumor vaccine 
designs.
METHODS
Patients, tissues and blood samples
AT/RT tissue samples (n=18) were obtained from tumor 
banks at the University Hospitals in Würzburg, Bonn, 
Heidelberg, Berlin, and Tübingen. In five patients 
treated in Tübingen and Würzburg, fresh tissue could 
be obtained directly from neurosurgical procedures. 
According to the requirements of the German HIT- 
Netzwerk, AT/RT diagnoses were centrally reviewed and 
confirmed in all 23 available cases by the DGNN refer-
ence neuropathology in Bonn. Tumor tissue samples 
have been snap frozen and stored in liquid nitrogen 
until usage. All samples were subject to ligandome 
analysis as described below. In 10 cases, reference DNA 
from peripheral mononuclear cells was available; thus, 
in these cases, whole exome sequencing and neoepi-
tope identification could be performed. In nine tumor 
samples, MPLA sequencing of the SMARCB1 locus was 
carried out to identify the nature of the SMARCB1 
mutation. The whole workflow of AT/RT tissue workup 
is detailed in online supplemental figure 1. For immu-
nohistochemistry, 17 additional formalin- fixed and 
paraffin- embedded AT/RT tumor tissues from the 
neuropathologies in Würzburg and München were used. 
Population coverage analysis for HLA class I and II was 
performed using the IEDB analysis resource (http:// 
tools. iedb. org/ population/).15 AT/RT subgroup infor-
mation was available for 12 of the tissue samples: five 
belonged to the MYC, four to the TYR, and three to the 
SHH subgroup, respectively.
HLA typing
HLA alleles for loci A, B, C, DRB1 and DQB1 were deter-
mined by standard sequencing procedures (sequence- 
based typing SBT, Protrans GmbH, Hockenheim, 
Germany or GenDx, The Netherlands), which provide 
high- resolution typing. Confirmatory typing was under-
taken by sequence- specific oligonucleotides (SSO, One 
Lambda or Olrup CareDx, San Francisco, USA) according 
to institutional regulations.
Immunohistochemistry
Paraffin- embedded samples (thickness 2 µm) of 17 AT/
RT tissue were deparaffinized with Xylol and Ethanol and 
subsequently stained with standard immunohistochem-
istry procedures against CD3 (dilution 1:150), HLA class 
I (clone EMR 8–5, Abcam, dilution 1:1600), HLA class 
II (clone CR3/43, Abcam, dilution 1:1000), and PD- L1 
(dilution 1:500). One day after primary antibody incu-
bation, slides were stained with streptavidin–peroxidase 
complex (BioGenex, Fremont, California, USA) for 10 
min and counterstained with Mayer’s hemalaun solution. 
Human tissue from tonsil (CD3, HLA class II), liver (HLA 
class I), and placenta (PD- L1) served as a positive control. 
Expression levels were evaluated semiquantitatively by two 
independent investigators and given as the frequency of 
positive cells per visual field. Ten visual fields per tumor 
were analyzed. For determining the PD- L1 expression 
level, the harmonized Cologne scoring system was used.16
Isolation of HLA ligands
HLA class I and clas II molecules were isolated using 
standard immunoaffinity purification.17 18 In brief, snap- 
frozen AT/RT tissue samples were minced in lysis buffer 
containing 10 mM CHAPS/PBS (AppliChem, St. Louis, 
Missouri, USA/Gibco, Carlsbad, California, USA) and 
one protease inhibitor tablet (Complete; Roche, Basel, 
Switzerland). We employed the pan- HLA class I specific 
antibody W6/3219 and the HLA- DR specific antibody 
L243,20 both produced in house (University of Tübingen, 
Department of Immunology) from HB- 95, and HB- 55 
hybridoma cell lines (ATCC, Manassas, Virginia, USA) 
respectively. Furthermore, the pan- HLA class II antibody 
Tü39 was employed21 and produced in house from a 
hybridoma clone previously described. Antibodies were 
covalently linked to to CNBr- activated Sepharose (GE 
Healthcare, Chalfont St Giles, UK). HLA molecules were 
purified by cyclically passing the cleared protein lysate 
from AT/RT tissue over two columns. The first column 
contained 1 mg of W6/32 antibody coupled to sepharose, 
whereas the second column contained equal amounts of 
Tü39 (0.5 mg) and L243 (0.5 mg) antibody coupled to 
sepharose HLA- DR1 is known to be expressed at higher 
levels than the other class II allotypes; therefore, the 
specific L243 mAb at the given stoichiometry was used.22 
Tü39 is used complementarily to pull down the remaining 
class II complexes. HLA–peptide complexes were eluted 
by repeated addition of 0.2% trifluoroacetic acid (TFA; 
Merck, Whitehouse Station, New Jersey, USA). Eluted 
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HLA ligands were purified by ultrafiltration using centrif-
ugal filter units (Amicon; Millipore, Billerica, Massachu-
setts, USA) with 3 kDa and 10 kDa pore size for HLA 
class I and HLA class II ligands, respectively. HLA ligands 
were desalted using ZipTip C18 pipette tips (Millipore). 
Extracted peptides were eluted in 35 µL 32.5% acetoni-
trile (Merck)/0.2% TFA, and vacuum- centrifuged to 2–5 
µL and resuspended in 25 µL of 1% acetonitrile/0.05% 
TFA. Samples were stored at −80°C until analysis by liquid 
chromatography- mass spectrometry/mass spectrometry 
(LC–MS/MS).
Analysis of HLA ligands by LC–MS/MS
Peptide samples were separated by reversed- phase liquid 
chromatography (nano- UHPLC, UltiMate 3000 RSLC-
nano; Thermo Fisher, Waltham, Massachusetts, USA) 
and analyzed in online- coupled LTQ Orbitrap XL mass 
spectrometer (Thermo Fisher). Samples were analyzed 
in three or five technical replicates. Sample shares of 
20% were trapped on a 75 µm×2 cm trapping column 
(Acclaim PepMap RSLC; Thermo Fisher) at 4 µL/min 
for 5.75 min. Peptide separation was performed at 50°C 
and a flow rate of 175 nL/min on a 50 µm×25 cm sepa-
ration column (Acclaim PepMap RSLC; Thermo Fisher) 
applying a gradient ranging from 2.4% to 32.0% of aceto-
nitrile over the course of 90 min. Samples were analyzed 
on an LTQ Orbitrap XL using a top five CID (collision- 
induced dissociation) method with survey scans at 60 k 
resolution and fragment ion detection in the ion trap 
(ITMS2) operated at normal scan speed. Fragmentation 
of HLA class I ligands was limited to precursors with a 
mass range of 400–650 m/z and charge states 2+ and 3+. 
For HLA class II ligands, a mass range of 300–1500 m/z 
with charge states ≥2 were selected for fragmentation.
Database search
The software Proteome Discoverer (V.1.3; Thermo 
Fisher) was used to perform database search using the 
Mascot search engine (Mascot 2.2.04; Matrix Science, 
London, UK). The human proteome as comprised in 
the Swiss- Prot database (http://www. unipr ot. org, status 
September 2013, 20,225 reviewed sequences contained) 
was used as reference database. The search combined 
data of technical replicates and was not restricted by 
enzymatic specificity. Precursor mass tolerance was set 
to 5 ppm and fragment mass tolerance to 0.5 Da. Oxida-
tion of methionine residues was allowed as a dynamic 
modification. False discovery rate (FDR) estmation was 
performed using the Percolator node23 and was set to a 
peptide spectrum match level FDR ≤5%. For HLA class I 
ligands, peptide lengths were limited to 8–12 amino acids 
(AAs); for HLA class II, peptides were limited to 8–25 
AA of length. Protein grouping was disabled, allowing 
all proteins that contain a given peptide to be annotated 
as peptide source proteins. Only HLA class I ligands 
mapping into one source protein alone were considered 
for this analysis (3244 potential targets). As a final step 
of quality control, binding prediction was performed 
employing NetMHC- 3.0 with a cut- off score of %rank <0.5 
for strong binders and <2 for weak binders.24
Whole genome DNA sequencing
Library preparation and whole genome sequencing of 
tumor and matching normal DNA from peripheral blood 
was carried out as described previously.25 Briefly, 1–5 µg of 
genomic DNA was fragmented to ~300 bp insert size using 
a Covaris device. Size selection was conducted by agarose 
gel excision. For paired- end library preparation, we used 
Illumina, Inc V.2 protocols. Sequencing was performed 
on HiSeq2000 machines at the German Cancer Research 
Center (DKFZ) Genomics and Proteomics Core Facility. 
Sequencing reads were mapped and aligned as describe.3 
Briefly, we called variants using samtools and vcftools on 
the tumor bam files. The called positions were looked 
up in the control bam file, and the resulting raw calls 
were filtered using different annotations and criteria to 
create a set of high confidence somatic single nucleotide 
variants (SNVs). Indels were called using the pipeline 
platypus.26 All coordinates used in the analyses are based 
on human reference genome assembly hg19, GRCh37 ( 
ncbi. nlm. nih. gov/ assembly/ 2758). Gene annotations are 
based on genecode annotation release 19 ( gencodegenes. 
org/ releases/ 19. html). Whole genome sequencing data 
have been deposited at the European Genome- phenome 
Archive, EGA Study Accession IDEGAS00001001297.
The obtained mutated and the corresponding wild-
type sequences were verified in Uniprot or Ensemble 
databases (https://www. uniprot. org/, http:// apr2018. 
archive. ensembl. org/ index. html). For each mutation 
a virtual 9mer- library was created moving the mutated 
AA from pos 1 to pos 9 and matched with the individual 
HLA class I type (HLA- ABC) on the NetMHCpan 4.0 
server (http://www. cbs. dtu. dk/ services/ NetMHCpan). 
For each mutation the best binding peptide was selected 
according to binding affinity and %rank.
Immunogenicity prediction tools
For in silico immunogenicity prediction, two different 
online platforms were used. VaxiJen2.0 is a publicly avail-
able online platform that uses an alignment- independent 
method for vaccine subunit prediction based on autocross 
covariance transformation (http://www. ddg- pharmfac. 
net/ vaxijen/ VaxiJen/ VaxiJen. html). AA properties 
(hydrophobicity, size and polarity) are transcribed in 
z descriptors independently from the corresponding 
HLA allele.27 Protein sequences of source proteins were 
entered in fasta format, and tumor was selected as target 
organism. As suggested before, we chose a threshold 
of 0.45 to define probable protective antigens, slightly 
higher sensitivity than initially proposed threshold of 
0.5.28 In order to consider also HLA restriction, we addi-
tionally chose the IEDB immunogenicity prediction tool 
(http:// tools. iedb. org/ immunogenicity).29 Since the 
original validation of this algorithm was performed only 
for nonamer- peptides we restricted our analysis to 9- mers 
and to the HLA molecules specified in the menu. Peptide 
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sequences of potential epitopes were entered, and the T 
cell recognition score was determined with a threshold 
of 0.1 was set to distinguish whether HLA- ligands were 
predicted to be ‘immunogenic’ or ‘non- immunogenic’. 
Additionally, the mean T cell recognition score was 
calculated for ligandome class I, ligandome cryptic, and 
neoantigenic peptides in order to compare immunoge-
nicity of these three distinctive groups. Furthermore, the 
frequencies of probably protective/immunogenic anti-
gens was calculated for the whole group as well as for 
the subgroups of strong, weak, or non- binders according 
NetMHC algorithms.
Gene ontology and protein network analysis
Gene ontology and functional annotations of source 
proteins were defined and analyzed using DAVID Bioin-
formatics Resources 6.8, NIAID/NIH (https:// david. 
ncifcrf. gov/ summary. jsp).30 Protein–protein interac-
tion networks and functional enrichment analysis of 
proteins from different peptide sources was performed 
using STRING (https:// string- db. org/ cgi/ input. pl).31 
For description of protein domains, the PFAM 32.0 data-
base was chosen (https://www. pfam. xfam. org). Overlap 
of ligandome source proteins was analyzed and visual-
ized using the BioVenn web application (https://www. 
biovenn. nl).32
Naïve CD8+ T cell priming and T cell expansion protocol
For T cell priming assays. we used a previously described 
protocol.33 34 In brief, naïve CD8+ T cells were isolated 
from the peripheral blood of healthy donors positive for 
HLA- A02*01 (n=4) or HLA- B07*02 (n=1) using a purifica-
tion of CD8+ events, followed by depletion with CD45RO 
and CD57 microbeads on LD and LS columns (Miltenyi, 
Bergisch Gladbach, Germany). Isolated naïve CD8+ T cells 
were incubated with IL- 7 overnight. The next day, T cells 
were washed and mixed with irradiated, matured autolo-
gous dendritic cells (DCs), pulsed with either the hetero-
clitic HLA- A02*01- restricted peptide Melan- A26- 35L as a 
control or the investigational peptides as indicated at 1 
µg/mL. interleukin (IL)- 21 (30 ng/mL, Peprotech) was 
added to the coculture on day 0 the next morning. IL- 7 
and IL- 15 (5 ng/mL, Peprotech) were added on days 3, 5, 
and 7, and cells were harvested on day 10, some of them 
after restimulation with the original peptide. The Melan- 
A26- 35L (ELAGIGILTV) and investigational peptides 
were purchased from jpt (Berlin, Germany). Harvested 
T cells on day 10 or 12 were analyzed for tumor necrosis 
factor alpha (TNFα)/interferon gamma (IFNγ) positivity. 
T cell responses three times above the negative control 
(autologous DCs without peptide) were considered posi-
tive and those above the background but <3× were consid-
ered intermediate.
T cell responses defined by specific IFNγ secretion 
were measured using a stimulation–expansion–restim-
ulation protocol35: peripheral blood mononuclear cells 
(PBMCs) were isolated by Ficoll, stimulated with mature, 
peptide- loaded autologous DCs at a 4:1 (T:DC) ratio and 
expanded subsequently with IL- 15 (5 ng/mL) for 12–14 
days. Medium and IL- 15 was refreshed every second or 
third day. On days 7 and 14, PBMCs were restimulated with 
the same peptide loaded DCs. Negative control was stim-
ulation with empty DCs (mature, autologous DCs without 
peptide loading). Six hours after the last restimulation, T 
cells were analyzed for IFNγ production by intracellular 
cytokine staining. Only T cell responses three times above 
the negative control (autologous DCs without peptide) 
were considered positive. In HLA class I assays, the CEF- 
pool peptide mix (jpt, Hamburg, Germany) was used as a 
positive control.
Identification of cryptic peptides
Cryptic HLA- I peptides were identified using Peptide- 
PRISM as described recently.13 De novo peptide 
sequencing was performed with PEAKS X (Bioinfor-
matics Solutions Inc, Canada).36 Raw data refinement was 
performed with the following settings: (1) merge options: 
no merge; (2) precursor options: corrected; (iii) charge 
options: no correction; (4) filter options: no filter; (5) 
process: true; (6) default: true; and (7) associate chimera: 
yes. De novo sequencing was performed with parent 
mass error tolerance set to 10 ppm. Fragment mass error 
tolerance was set to 0.15 Da, and enzyme was set to none. 
The following variable modifications have been used: 
oxidation (M), pyro- Glu from Q (N- term Q), and carba-
midomethylation (C). A maximum of three variable post- 
translational modifications were allowed per peptide. Up 
to 10 de novo sequencing candidates were reported for 
each identified fragment ion mass spectrum, with their 
corresponding average local confidence score. Because 
we applied the chimeric spectra option of PEAKS X, two 
or more TOP10 candidate lists could be assigned to a 
single fragment ion spectrum. Two tables (‘all de novo 
candidates’ and ‘de novo peptides’) were exported from 
PEAKS for further analysis.
All de novo sequence candidates were matched against the 
six- frame translated human genome (hg38) and the three- 
frame translated human transcriptome (ENSEMBL 90) using 
Peptide- PRISM. Results were filtered to 10% FDR for each 
category (CDS, UTR5, OffFrame, ncRNA, UTR3, intronic, 
and intergenic). NetMHCpan 4.0 was used to predict binding 
affinities for all identified HLA- I peptides for all HLA alleles 
of the corresponding patient. The allele with the minimal 
rank reported by NetMHCpan was annotated. As per default, 
we used a cut- off of 0.5% rank for strong binders and 2% 
rank for weak binders.
Identification of cryptic peptides from the glioblastoma 
(GBM) data set37 has been performed in the same way 
using Peptide- PRISM. Comprehensive results have been 
published recently.13
Synthetic peptides were analyzed on an LTQ- Orbitrap 
Velos Pro (Thermo Scientific) equipped with a PicoView 
Ion Source (New Objective) and coupled to an EASY- nLC 
1000 (Thermo Scientific). Peptides were loaded on capillary 
columns (PicoFrit, 30 cm × 150 µm ID, New Objective) self- 
packed with ReproSil- Pur 120 C18- AQ, 1.9 µm (Dr. Maisch) 
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and separated with a 30 min linear gradient from 3% to 30% 
acetonitrile and 0.1% formic acid and a flow rate of 500 nL/
min. MS scans were acquired in the Orbitrap analyzer with a 
resolution of 30,000 at m/z 400, MS/MS scans were acquired 
in the Ion Trap analyzer with normal scan rate using CID frag-
mentation with 35% normalized collision energy. A TOP10 
data- dependent MS/MS method was used; dynamic exclu-
sion was applied with a repeat count of 1 and an exclusion 
duration of 120s; singly charged precursors were excluded 
from selection. Minimum signal threshold for precursor 
selection was set to 20,000. AGC was used with AGC target 
with a value of 1e6 for MS scans and 1e4 for MS/MS scans. 
Lock mass option was applied for internal calibration in all 
runs using background ions from protonated decamethylcy-
clopentasiloxane (m/z 371.10124).
Statistical analyis
Concordance between different IHC markers was analyzed 
by Pearson linear regression analysis. To linearize distribution 
of the percentages of marker positive cells in neuropatholog-
ical slides, data were logit- transformed and plotted by Pearson 
linear regression using SPSS V.26. The correlation coefficient 
r specifies strength and direction of the correlation, the p 
values indicate whether the correlation coefficient r is signifi-
cantly different from 0. Differences between two groups were 
assessed by non- parametric Mann- Whitney U test assuming 
unequal variances. For comparison of multiple groups, the 
non- parametric Kruskal- Wallis rang- sum test was used. For 
differences within a group, the two- tailed t test was applied. 
P<0.05 was considered statistically significant.
RESULTS
Immunohistochemical landscape of AT/RT tissue
First, we analyzed an independent cohort of 17 AT/RT 
tissues for the prevalence of T cells, HLA and PD- L1 
molecules. Diagnosis of AT/RT was confirmed by central 
neuropathological review in all cases. The 1.8%±5.1% of 
all cells within AT/RT tissues represented CD3+ T cells. 
HLA class I and to a lesser degree also class II molecules 
were found to be expressed on tumor cells. PD- L1 expres-
sion level on tumor cells was 5.1%±6.8% as determined 
by the Cologne scoring system (figure 1 A+B). Linear 
regression revealed a weak inverse correlation between 
HLA class I and CD3 expression (figure 1C) and positive 
correlation between HLA class I and PD- L1 (figure 1D). 
From one of the freshly obtained tumor samples, we were 
able to create a primary rhabdoid cell line. On this cell 
line, we could confirm constitutive expression of HLA 
class I and IFNγ-inducible upregulation of HLA class II 
and PD- L1 molecules (figure 1E).
LC-MS/MS-based immunopeptidome profiling reveals AT/RT-
associated HLA source proteins and HLA class I and II ligands 
eligible for immunotherapy approaches
Twenty- three AT/RT tumor samples could be retrieved 
from five tumor cell banks throughout Germany with a 
centrally confirmed diagnosis of an AT/RT. The cohort 
included a total of 51 different HLA class I allotypes, 
HLA- A*03:01 (n=9) being the most frequent, followed 
by HLA- A*02:01 (n=6), HLA- C*04:01 (n=6), and HLA- 
C*07:01 (n=6, online supplemental figure 2). Among 
the world’s population, 99.9% of individuals carry at 
least one HLA class I allotype that is represented within 
the here analyzed AT/RT cohort (online supplemental 
figure 2).15 38 The comparative cohort of benign tissue 
donors showed an HLA allotype population coverage 
of 99.8% (online supplemental figure 2) and matched 
100% of HLA- A allotypes (13/13), 72% of HLA- B allo-
types (13/18), and 92% of HLA- C allotypes (11/12) of 
the AT/RT cohort.
LC- MS/MS analysis of these 23 AT/RT tumor samples 
identified 7628 unique HLA class I peptides (range 
13–1372, mean 459 per sample) (figure 2A) from 4807 
source proteins at a local PSM- level FDR of 5%. The 
in- house HLA class I benign cohort contained 282 
tissues covering among others brain (n=5) and cere-
bellum (n=5) (HLA Ligand Atlas Paper Version 2017, 
extended with ligandomes from disease- free ovary). 
Based on these two datasets, we performed comparative 
HLA class I ligandome profiling to identify AT/RT- as-
sociated source proteins (figure 2B). We identified 55 
HLA class I source proteins exclusively presented on 
AT/RT samples and from these 56 distinct HLA class I 
peptide ligands as candidates for downstream immuno-
genicity analysis (figure 2B, online supplemental table 
1). The majority of AT/RT- associated source proteins 
(48/55) were individual to each AT/RT tumor, while 
only six were shared between two patients, and one was 
shared between tumor and ascites sample of the same 
patient.
With respect to HLA class II, 30 distinct class II allotypes 
were identified in the AT/RT patient cohort, with HLA- 
DQB1*03:01 (n=27) being the most frequent, followed by 
HLA- DRB1*03:01 (n=20) and HLA- DRB1*15:01 (n=20). 
Among the world’s population, 99.7% of individuals carry 
at least one HLA class II allotype encompassed in the AT/
RT cohort, with an average hit number of 3.71 per indi-
vidual (online supplemental figure 2).
LC- MS/MS analysis of the AT/RT HLA ligandome 
revealed 3827 distinct HLA class II peptide sequences 
(range: 9–698, mean per sample 214) (figure 2A) origi-
nating from 1517 source proteins at 5% local PSM- level 
FDR. Our HLA class II benign cohort entails 132 ligan-
domes from benign samples, covering among other 
tissues, 5 cerebellum and 5 brain samples. Unfortunately, 
most benign HLA class II ligandomes lack HLA class 
II typing. By comparing the AT/RT and benign tissue 
cohort regarding single mapped source proteins, we were 
able to identify 139 AT/RT- associated HLA class II source 
proteins associated to 122 distinct HLA class II ligands 
(figure 2C, online supplemental table 1). Remarkably, 
multiple AT/RT- associated source proteins were shared 
among patients: one was presented in 8 different AT/RT 
samples, 3 additional source proteins were shared between 
four AT/RT patients and 11 were shared between two 
patients. As observed for HLA class I AT/RT- associated 
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Figure 1 Immunohistochemistry of AT/RT tissues. Seventeen AT/RT tissues were evaluated for expression of CD3, HLA- ABC, 
HLA- DR, and PD- L1 on tumor cells. (A) Mean values±SD for all four markers, 10 visual fields were evaluated in each tumor 
sample. (B) Representative examples for each of the four markers. (C and D) Linear regression analysis of HLA- ABC expression 
against CD3+ T cell infiltration (C) and PD- L1 expression (D). Data are plotted after logit- transformation, correlation coefficient r 
indicates strength and direction of the concordance, the p value specifies the difference of r from 0. (E) Flow cytometric analysis 
of one primary rhabdoid cell line. Shaded line represents unstained control, blue line represents constitutive expression, red line 
represents expression after IFNγ stimulation of tumor cell line. AT/RT, atypical teratoid/rhabdoid tumor.
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Figure 2 HLA class I and II peptide identifications (A) number of identified peptides in each tumor sample for HLA class I 
(upward columns) and class II (downward columns). Gray versus black shading illustrates predicted or non- predicted binding 
of peptides to self- HLA allotypes in the respective patients. Red squares (right y- axis) show purity of peptide pools, that is, the 
ratio of predicted binding versus total number of identified peptides. (B) Waterfall plot demonstrating overall source protein 
identifications for HLA class I ligands (x- axis) in benign (green, downward columns) and AT/RT tissue (blue, upward columns) 
and their frequency in the respective patient cohort. Tumor- exclusive are only the source proteins in the far left red boxes that 
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source proteins, the majority (124) was unique to each 
patient (figure 2C).
Cryptic peptides in AT/RTs ligandome
Next, we extended our search to identify cryptic HLA 
class I peptides from allegedly non- coding regions of 
the human genome. To this end, we applied a recently 
introduced approach (Peptide- PRISM) that combines de 
novo peptide sequencing, highly efficient string search, 
mixture modeling, and search space stratified filtering 
of the FDR.13 De novo sequencing was performed for all 
LC- MS/MS data of the 23 AT/RT tumors samples with 
PEAKS X. Peptide- PRISM was used to match all de novo 
sequencing candidates against the three- frame trans-
lated human transcriptome and the six- frame translated 
human genome. Two hundred and nine cryptic peptides 
were identified (FDR 10%), 158 of which were predicted 
as binder (rank <2%) to one of the corresponding patient 
HLA alleles by NetMHCpan 4.0. The distribution of the 
158 cryptic peptides among the different categories is 
shown in figure 3A. The highest number of peptides 
derived from non- canonical open reading frames close to 
the canonical translation start site (categories UTR5 and 
OffFrame). These cryptic peptides presumably originate 
from translational misinitiation. An example of such a 
peptide is shown in figure 3B.
In order to identify potentially tumor- associated or 
tumor- specific cryptic peptides, we filtered out all cryptic 
peptides that have previously been identified within the 
human HLA ligand atlas project (https:// hla- ligand- 
atlas. org).39 Sixty- one of the 158 cryptic binding peptides 
were identified only in AT/RT tumor samples but not in 
benign tissue (online supplemental figure 2). In addi-
tion, we compared the cryptic peptides identified in AT/
RT samples with cryptic peptides previously identified in 
GBM tumor tissue as well as plasma- soluble HLAs.37 A 
complete list of all cryptic peptides from these samples 
has been recently published.13 Twenty of the 61 (33%) 
cryptic peptides have been recurrently identified in 
either at least two AT/RT patients (9/61, 15%) or AT/RT 
and GBM patients (11/61, 18%), for example, the cryptic 
peptide LSLEEGIVEV derived from an intron of HIPK3 
is identified recurrently in five AT/RT patients (online 
supplemental figure 2). We selected six cryptic peptides 
from different categories for analyzing their immuno-
genicity (see further). Fragment ion spectra of these six 
synthetically preparated peptides were generated for vali-
dating the peptide identification. For all but one peptide 
(MPISLVQLL) comparison of the fragment ion spectra 
obtained from AT/RT samples with the fragment ion 
spectra of the corresponding synthetic peptide confirmed 
the initial peptide identification (online supplemental 
figure 3).
Analysis of the distribution of the different peptide 
classes (class I natural vs cryptic and class II) to the overall 
ligandome composition between the established A/RT 
molecular subgroups (MYC, SHH, and TYR) revealed 
no significant differences compared with the group as a 
whole (figure 3C) .
Non-synonymous mutations in AT/RTs
Furthermore, we were interested to examine whether the 
oncogenic SMARCB1 mutation can give rise to immu-
nogenic peptides. After ligandome analysis, additional 
tissue was left in 18 cases, in nine of these also PBMCs 
were available. In the cases with tumor tissue only, MPLA 
sequencing of the SMARCB1 locus was performed. In 
these assays, only homozygous or heterozygous deletions 
but no SNVs of the SMARCB1 locus were detectable, 
making the existence of neoepitopes in this region unlikely 
(online supplemental table 3). In the other nine AT/RT 
cases, we isolated genomic DNA from fresh- frozen AT/
RT tissues and corresponding PBMCs for whole- exome 
sequencing (WES). As expected, the overall number of 
non- synonymous mutations was low (median 16, range 
1–155). Five tumors harbored ≤7 SNV, whereas four 
tumors displayed a higher number of SNVs (99, 112, 137, 
and 155). Two of these belonged to the SHH, one each 
to the TYR and MYC group, respectively. Also in WES, no 
non- synonymous mutations in the SMARCB1 locus could 
be identified. The 24 most frequently mutated genes and 
their chromosomal location are shown in figure 3D.
To identify potential neoantigenic epitopes from these 
SNVs, overlapping 9- mer peptide libraries moving the 
mutation from pos 1 to pos 9 were generated and analyzed 
for predicted binding to all HLA alleles of the individual 
patient. The peptide with the best binding score for any 
of the patients’ HLA alleles was selected. A complete 
list of all in silico predicted neoantigens is provided in 
online supplemental table 4. None of these neoantigenic 
peptide sequences could be verified in the MS data.
Immunogenicity of ligandome peptides
To assess potential immunogenicity of all identified, AT/
RT- associated HLA class I peptides, we first compared in 
silico predicted major histocompatibility complex (MHC) 
binding affinity using NetMHCpan 4.0. Whereas binding 
affinity of neoantigenic and ligandome cryptic peptides 
was almost identical, ligandome- identified canonical class 
I peptides displayed a significantly higher binding affinity, 
suggesting that these peptides have undergone an in vivo 
selection process in the class I peptide loading complex 
(figure 4A).
MHC- I binding algorithms mainly rely on binding of 
certain AAs to anchor residues at P1, P2, and P9 of the 
MHC- I peptide binding groove. Recently, several in silico 
immunogenicity prediction tools have used alternative 
computational methods to assess T cell receptor recogni-
tion of a peptide MHC complex, for example, based on 
the presence of large, aromatic residues at P4, P5, and 
P6 of a peptide (IEDB database) or the hydrophobicity, 
molecular size and polarity of whole protein sequences 
(VaxiJen server). The IEDB database requires knowledge 
of the individual peptide sequence, and only a limited set 
of validated HLA alleles can be analyzed with this tool. 
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Figure 3 Identification of cryptic class I peptides. One hundred and fifty- eight class I peptides have been identified and 
predicted as binder to one of the corresponding patient alleles in AT/RT tumor samples. (A) Distribution of identified cryptic 
peptides among genomic categories. (B) Example of a cryptic HLA peptide from 5’-UTR. The peptide was identified in two AT/
RT patients but not in benign tissue. The peptide is predicted as a strong binder (RANK <0.5%) by NetMHCpan in both patients 
for HLA- B*51:01 and HLA- B*07:02, respectively. (C) Columns display the relative contribution of different class I and class II 
peptides to the overall ligandome, numbers indicate the mean number of peptides per group. P values were determined using 
the non- parametric Kruskal- Wallis test. (D) Most frequently mutated proteins and their localization on the 23 chromosomes. 




















10 Marcu A, et al. J Immunother Cancer 2021;9:e003404. doi:10.1136/jitc-2021-003404
Open access 
Figure 4 Immunogenicity of HLA class I peptides. (A) Peptides sequences of natural and non- canonical HLA ligands identified 
by MS as well as in silico predicted neoepitopes were ranked according to the NetMHCpan4.0 algorithm. The best binding HLA 
allele from each tumor sample was chosen. Pie charts below the graph show classification of %rank values into strong (≤0.5), 
weak (0.5–2) and non- binders (>2); n indicates the total number of peptides per group. (B) Peptides with an HLA ligand listed 
in the IEDB data base were alternatively scored for immunogenicity according to the IEDB algorithm; n indicates the number 
of peptides, which could be submitted to the IEDB server. (C) Highly purified naïve CD8+ T cells from five healthy HLA- A*02:01 
(n=4) and HLA- B07*02 (n=1) positive donors were cocultured for 12 days with peptide- loaded autologous DCs in the presence 
of IL –7, –15, and −21, restimulated and assayed for IFNγ/TNFα production. A response 3× above background (empty dendritic 
cells (DCs)) was considered as positive (green bars); responses above background but not positive were defined as intermediate 
(gray bars). N indicates the total number of wells tested in the respective peptide group. (D) Pseudo- color dot plots display 
three representative examples of positive responses for ligandome natural, cryptic, and neoantigenic epitopes, respectively. 
Negative controls (cells stimulated with empty DCs) are shown below each plot. For the complete data set of priming assays, 
please refer to online supplemental figure 4. Upper numbers in the quadrants show percentages of CD8+IFNγ+ and/or TNFα+, 
while specifications in the lower right quadrant indicate number of positive experiments against the amount of donors tested as 
well as the HLA restriction used. The bold and red colored amino acid indicates the mutation. P values were determined using 
Mann- Whitney or Kruskal- Wallis test. IFNγ, interferon gamma; TNFα, tumor necrosis factor alpha.
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For IEDB, we considered only peptides with the validated 
length of nine AAs. IEBD generally yielded lower frequen-
cies of peptides with a positive prediction (37.8%–52.3%) 
than the VaxiJen platform (62.3%–77.9%). Using the 
IEDB prediction algorithm AT/RT ligandome class I 
peptides had higher immunogenicity prediction scores 
than neoantigenic peptide sequences (figure 4B). In 
contrast, the VaxiJen server favored neoantigenic and 
ligandome cryptic over ligandome class I source proteins 
(data not shown). There was no correlation between 
MHC binding affinity and either IEBD or VaxiJen scores 
(data not shown).
In addition to these in silico predictions, we tested the 
immunogenicity of the identified peptides in an in vitro 
priming assay. This assay uses highly purified naïve CD8+ 
T cells from healthy donors as starting population and 
autologous DCs as stimulators, thereby closely mimicking 
a vaccination scenario in vivo.33 34 We focused on two HLA 
alleles with a high prevalence in our general population 
(HLA- A*02:01 and HLA- B*07:02) and tested all identi-
fied peptides for binding to these two alleles. From the 
resulting binders we choose 12, 6, and 9 peptides from 
the list of ligandome- identified canonical class I, cryptic, 
and neoantigenic peptide pools, respectively, with a pref-
erence for strong binders (23 strong and 4 weak- binders). 
Ninety- two per cent (11 out of 12), 83% (5 out of 6), and 
89% (8 out of 9) of the tested peptides yielded at least one 
positive well with no significant difference between the 
groups (figure 4C, the complete data set of priming assays 
is shown in online supplemental figure 4), confirming 
that the majority of peptides from the different pools can 
be recognized by naïve T cells. We found a trend for a 
correlation between predicted HLA binding and cyto-
kine reactivity as well as more cytokinepos T cells in strong 
versus weak binders, but due to the large variation among 
the strong binders and the low number of selected weak 
binding peptides, these tests failed to reach significance 
(online supplemental figure 4).
Furthermore, we investigated whether memory 
responses against these peptides can be detected in AT/
RT patients. PBMCs from four AT/RT patients were 
assayed in restimulation experiments for IFNγ response 
against peptides fitting their HLA restrictions. For HLA 
class I peptides, we screened all peptides for poten-
tial binding to HLA- A and HLA- B alleles from these 
four patients and identified 17, 18, 23, and 32 suitable 
peptides for restimulation experiments. As demon-
strated in figure 5A, only one ligandome peptide (FPIL-
STILL from the CCG4 source protein) showed a positive 
response in one patient, whereas all other experiments 
remained negative, confirming that constitutive CD8+ T 
cell responses against tumor- associated peptides without 
prior vaccination are exceedingly rare. The same assay 
was repeated for the 18 HLA class II peptides that were 
identified more than once in AT/RT tumor samples with 
gating on CD3+CD4+ T cells (figure 5B). Notably, 15/18 
class II peptides showed at least one positive response, 
two peptides even gave positive results in three out of four 
patients tested. To analyze whether these responses are 
specific for patients with AT/RT, we repeated this exper-
iment with PBMCs from three high- grade glioma (HGG) 
patients and three healthy controls. In HGG patients, 
10/18 peptides yielded a positive response, however, only 
in one patient each. The LSIEEDVLAA peptide derived 
from THMS1 source protein (detectable in eight different 
AT/RT samples) showed a more substantial response in 
one HGG patient (figure 5B). In PBMCs from healthy 
controls only eight faint responses at the detection limit 
in singular patients were measurable. These data indicate 
that Thelper cells of AT/RT patients have been exposed 
to HLA class II ligandome peptides before, which has 
resulted in memory formation in more than 80% of tested 
peptides. This phenomenon seems to be tumor specific 
as such responses were less detectable in HGG patients 
and virtually absent in healthy donors. For HLA class I 
peptides no such memory formation could be observed.
Gene ontology and protein network analysis
Having identified tumor- exclusive peptides from four 
different sources (ligandome HLA class I and II peptides 
from natural proteins, ligandome class I cryptic, and 
neoantigenic peptides), we mined these data for existing 
overlap between the respective source proteins or 
pathway enrichment. Functional annotation using the 
DAVID Bioinformatics database revealed little similarity 
in terms of biological process or molecular function (online 
supplemental table 5). Of note, the four different peptide 
sources covered distinct cellular compartments. In line 
with previous reports, HLA class I ligandome peptides 
were mainly derived from cytosolic proteins, whereas 
HLA class II ligandome source proteins were allocated 
to the plasma membrane. AT/RT neoantigens covered 
external and internal membrane proteins (plasma, Golgi, 
endo-/lysosomal membranes, junctions, MHC class II 
complex), whereas source proteins of ligandome cryptic 
peptides were primarily assigned to the nucleoplasm 
(figure 6A). Functional enrichment analysis of protein 
networks showed four, three, and one enriched protein 
domains within neoantigenic, cryptic and HLA class I 
source proteins, respectively, whereas for HLA class II no 
such enrichment could be detected (figure 6B). Likewise, 
only the network of mutated proteins displayed a signifi-
cantly higher number of interactions than expected, with 
a cluster in HLA and HLA- associated genes (figure 6C), 
which is consistent with the high number of mutations on 
chromosome six (figure 3C). Taken together, these data 
indicate that source proteins from different AT/RT- spe-
cific peptide pools cover a wide variety of biological func-
tions and show little enrichment of particular protein 
domains. However, at least in AT/RTs, the different 
peptide sources seem to emerge from distinct cellular 
compartments.
Overlap of AT/RT ligandome with other tumor-specific 
ligandomes
Finally, we matched our list of HLA class I AT/RT 
ligandome peptides from natural source proteins with 
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published data sets of tumor- specific ligandomes from 
other cancer entities. Selection criterion for these 
comparators was their tumor specificity, that is, the exclu-
sion of peptides also found in other benign tissues. We 
used two published data sets from GBM,37 40 and one from 
ovarian cancer41 and renal cell carcinoma28 each. While 
6% of source proteins overlapped between the two GBM 
datasets, only 2% could be found simultaneously in AT/
RT and GBM. No overlap existed between AT/RTs and 
the two non- CNS cancers (ovarian and renal; figure 6D). 
The more substantial overlap (33%) between AT/RT 
and GBM in the cryptic ligandome has been mentioned 
previously.
DISCUSSION
Tumor immunosurveillance represents a difficult task 
for immunity, since cancer cells are a derivate of self and 
thymic selection has trained T cells for self- tolerance. 
The vast majority of the several hundred thousand MHC 
molecules on a cancer cell is loaded with self- peptides. 
For tumor eradication, both the affinity between peptide 
and MHC42 and between TCR and peptide–MHC 
complex43 has been demonstrated to be of critical impor-
tance. Therefore, the search for optimal anticancer T 
cell epitopes focuses either on high affinity peptides 
from natural proteins, which are normally not expressed 
on benign tissue or on peptides derived from sequences, 
which are not part of the thymic Aire+ medullary epithe-
lial cell library effective during T cell selection. From the 
latter category, peptides covering a cancer- specific muta-
tion have been intensely investigated in recent years. 
Although T cell responses against such neoantigens 
derived from non- synonymous mutations undoubtedly 
exist and can be boosted by vaccination approaches,44 
detection of neoantigenic peptides within the HLA 
ligandome has been exceedingly rare.45 One study esti-
mated that less than 1% of all non- silent mutations are 
represented in the HLA ligandome.46 Given the fact that 
Figure 5 Recall responses against HLA class I and class II peptides in AT/RT patients. (A) Peptides sequences of natural and 
non- canonical HLA class I ligands identified by MS as well as in silico predicted neoepitopes were screened for binding to the 
HLA- A and HLA- B alleles of four AT/RT patients, in whom PBMCs were available. The resulting 17, 18, 23, and 32 peptides 
were used to activate PBMCs from these four patients. Column graphs show frequencies of CD8+IFNγ+ T cells after 1–2 rounds 
of restimulation. Pie charts above source protein names display the frequency of positive tests (>3× above background, in 
yellow). Zebra plots below the charts show one representative example of the onliest positive result in a natural ligandome 
peptide and two negative wells from a cryptic and neoantigenic peptide from the same patient plus controls. (B) The 18 
ligandome class II peptides that were detected in more than one tumor sample were used to activate CD4+ T cells from four 
AT/RT patients. PBMCs of three patients with high- grade gliomas and three healthy individuals served as controls. Column 
graphs show frequencies of CD4+IFNγ+ T cells after one to two rounds of restimulation. Pie charts above source protein names 
display the frequency of positive tests (>3× above background, in yellow). Zebra plots below the charts show five representative 
examples of positive responses to class II peptides from different AT/RT patients. AT/RT, atypical teratoid/rhabdoid tumor; MS, 
mass spectrometry; PBMCs, peripheral blood mononuclear cells.
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most tumors harbor less than 100 somatic mutations and 
that at least three identical neighboring peptide–MHC 
complexes are required to trigger cytotoxicity,47 the 
search for neoepitopes has been extended to so- called 
non- mutated neoantigens, that is, epitopes derived from 
non- canonical translated or novel protein isoforms.48 This 
new category of HLA- bound epitopes has originally been 
discovered in the ligandome of normal cells but recently 
also confirmed in adult tumors.49 50 Pediatric cancers 
generally rank among tumors with a low mutational 
burden. AT/RTs are a typical representative of this cate-
gory, as one deleting mutation in the SMARCB1 gene 
is sufficient for oncogenesis.51 Since SMARCB1 dele-
tion leads to widespread epigenetic dysregulation, AT/
RTs are considered epigenetic diseases. Yet, AT/RTs are 
infiltrated by immune cells,7 and subgroups of AT/RTs, 
especially the MYC and SHH subsets,9 11 even show a pref-
erence for cytotoxic T cells.9 10 Our IHC data confirm 
that approximately 2% of all cells within the AT/RT 
microenvironment are T cells. The negative correlation 
Figure 6 Gene ontology and network analysis of AT/RT peptides. (A) Functional annotation ‘cellular compartment’ of the four 
different AT/RT peptides sources defined by DAVID Bioinformatics Resources 6.8. (B) Listing of enriched protein domains in the 
four source protein cohorts. (C) Protein network analysis using string. (D) Overlap of the AT/RT peptide pool with four published 
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between CD3 and HLA- ABC could be interpreted as 
HLA- downmodulation as part of a reversible, epigeneti-
cally regulated tumor escape mechanism.52 However, the 
accumulation of mutations on chromosome 6 and the 
identification of MHC mutations as the only significant 
network cluster in gene ontology analysis of WES data 
could also point toward partial HLA loss as an AT/RT- in-
trinsic ‘hard’ lesion.53 This issue, including strategies to 
restore HLA expression, warrants further investigation. 
Furthermore, our data confirm that neoepitopes derived 
from non- synonymous mutations are not presented on 
the surface of AT/RT cells (at least not within our range 
of detection), as no SMARCB1- derived peptide could be 
identified. All analyzed patients in our cohort exhibited 
truncating mutations, making generation of mutation- 
derived peptides even more unlikely. Unexpectedly, four 
AT/RTs showed 100 or more mutations with no prefer-
ence for one of the recently consented MYC, SHH, and 
TYR subgroups,3 4 but also in these cases, no neoanti-
genic peptide could be confirmed in the ligandome 
data. Furthermore, we could not find differences in 
peptide composition between the subgroups, confirming 
DNA methylation data that rather the type of immune 
cell infiltration than the subgroup determines survival 
outcome.11 How the ligandome shapes different immune 
cell infiltration patterns remains to be elaborated in 
future studies.
Ligandome analyses have been performed in 
several adult cancer types such as melanoma,45 GBM,40 
colorectal,54 lung,55 renal cell cancer (RCC),56 or ovarian 
cancer41 as well as in hematological malignancies such as 
multiple myeloma57 and leukemias.58 Our study in AT/
RTs represents the first pediatric tumor entity analyzed. 
As in their adult counterparts, the AT/RT ligandome is 
primarily composed of peptide ligands from a wide variety 
of natural proteins with little overlap between individual 
samples, making it unlikely that entity- spanning universal 
HLA class I epitopes do exist. Overlap was higher for 
HLA class II peptides, as epitopes derived from THEMIS, 
AAGAB, ASB16, and EXTL3 proteins were found in 
more than two tumors in our cohort. These targets can 
be regarded as bona fide AT/RT HLA- II ligands, since 
identification by MS has demonstrated highest fidelity for 
ligands with real MHC II binding.59 For HLA- I, only four 
peptides were detected in two tumors; all remaining were 
unique to one specific tumor. A small overlap existed with 
two published GBM data sets, suggesting that the ligan-
dome of CNS tumors is more closely related than that of 
extracranial cancers. No viral, or retroviral sequences as 
suggested,10 could be identified in the AT/RT immuno-
peptidome. With regard to vaccine development, these 
data highlight the necessity to characterize the individual 
HLA ligandome of each tumor as part of a personalized 
molecular diagnostic workup. Given the higher overlap 
within the HLA class II peptidome and the broader reac-
tivity of CD4+ T cells, it is conceivable that an HLA class II 
peptide mix might cover the majority of AT/RT patients. 
However, such an approach requires more ligandome 
and immunogenicity data.
Our epitope discovery platform additionally included 
the search for peptides derived from non- canonical 
protein translation. Such false or aberrant translation 
events result in small and extremely short- lived intracel-
lular proteins, which are hard to detect by conventional 
proteomics but can nevertheless enter the proteasomal 
pathway. Intriguingly, half- life of a cryptic pMHC complex 
is about 90 times longer than that of the cytosolic source 
protein.60 Cryptic peptides have recently been reported 
to make up to 15% of the HLA class- I ligandome in 
normal as well as in malignant cells.13 14 HLA class II 
cryptic peptides are unlikely to exist since class II epitopes 
are longer and derived from large and stable internalized 
extracellular proteins.61 Cryptic peptides might represent 
a new and preferential source of targetable antigens for 
cancer immunotherapy,49 as they are abundant, tumor 
specific and possibly shared between different tumors.61 
Since they are most likely not part of the library of self- 
peptides presented during thymic T cell selection, they 
can be regarded as non- mutated neoantigens. We were 
able to identify 61 tumor- specific, HLA- binding cryptic 
peptides not being present in the benign dataset,39 thus, 
more than half of the 116 HLA class I peptides in AT/RTs 
originated from non- canonical source proteins. Out- of- 
frame translations and gene products from 5′UTR regions 
dominated as reported previously.14 HLA peptides catego-
rized as ‘intronic’ are not necessarily derived from intron 
retentions but might also derive from an overlapping 
aberrant transcript that is located just by chance within 
an intronic region. Furthermore, since our approach 
did not include RNA- seq analysis, we could not identify 
neojunction peptides derived from alternative splicing 
sites, since the latter are not part of the ENSEMBLE 90 
database. Future studies will have to include RNA- seq 
data to allow identification of this emerging class of novel 
tumor antigens. Thirty- three per cent of these peptides 
were repeatedly found either in several AT/RT samples 
or in a published GBM dataset.13 Notably, the peptide 
repertoire overlap between AT/RT and GBM was higher 
for cryptic than for natural HLA ligands. HLA- I binding 
prediction showed that ligandome peptides from natural 
proteins had significantly stronger HLA binding than 
cryptic peptides, indicating that the former have under-
gone a more stringent intracellular selection process. 
Noteworthy, when we combined peptide ligands from all 
three subtypes, suitable ligands were found for all patients 
with a median of 13 peptides per tumor (range 3–34), 
indicating that even low- mutational pediatric tumors give 
rise to actionable tumor- associated T cell targets.
In contrast to other studies, which detected small sets 
of entity- spanning antigens in hematological malignan-
cies58 and GBMs,62 we could not identify network clus-
ters for HLA I or II ligands using gene ontology tools. 
Since these algorithms were trained on larger data sets, 
it is possible that we missed them due to the rather low 
number of source proteins in our data (<140). However, 
 on N
ovem
















15Marcu A, et al. J Immunother Cancer 2021;9:e003404. doi:10.1136/jitc-2021-003404
Open access
the allocation of source proteins to specific cellular 
compartments followed clear patterns. As expected, 
source proteins for natural class I ligands were mainly 
located in the cytoplasm, whereas class II peptides derived 
from membrane bound or intracellular vesicle associated 
proteins. Cryptic peptides were annotated to the nucleo-
plasm and to a lesser extent to the trans- Golgi network, 
suggesting that cryptic peptides are representatives of this 
tumor cell compartment on the cell surface. Thus, we 
postulate that cryptic peptides are an important compo-
nent of the immunological homunculus of the AT/RT 
cell (figure 7). However, in contrast to its fixed neuro-
logical counterpart, the immunological homunculus is 
most likely highly dynamic, since inflammation,63 but also 
therapeutic elements such as chemotherapy or kinase 
inhibitors can profoundly impact on HLA expression and 
unmask new peptide epitopes.64 Since the cryptic ligan-
dome of only few tumors has been unveiled so far, we do 
not know whether the rather high contribution of cryptic 
peptides to the ligandome is an AT/RT- specific phenom-
enon and related to the epigenetic dysregulation of this 
tumor or whether frequencies of >50% can be found in 
other tumors as well. Certainly, the stability and compo-
sition of the immunopeptidome during therapy and 
disease progression requires more active investigation.
A basic question in tumor vaccine design is whether 
selected peptides can give rise to T cell responses in vivo. 
We tried to address this issue on two levels: the level of de 
novo naïve T cell priming (mimicking a vaccine response) 
and on the level of existing recall responses in AT/RT 
patients. For level one testing, we chose a validated T cell 
assay in which highly purified naïve CD8+ T cells were 
primed on peptide- loaded autologous dendritic cells.33 34 
In this assay, more than 80% of tested HLA- I peptides 
from natural, cryptic or neoantigenic origin yielded 
at least one positive response, suggesting that all three 
peptide sources are suitable for vaccine design. We found 
a weak, non- significant correlation between in silico 
Figure 7 The immunological homunculus of AT/RTs. Illustration of the immunological representation of different cellular 
compartments of the AT/RT cell on HLA class I (left) and HLA class II molecules (right). Portion of the respective wings 
reflects the contribution of each peptide source to the class I or II peptidome. The size of the compartments in the outer circle 
corresponds to the representation of the compartment in the peptidome. AT/RTs, atypical teratoid/rhabdoid tumor.
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HLA binding prediction and immunogenicity as well as 
a trend for more cytokine reactive T cells after stimula-
tion with strong binding peptides. However, our analysis 
was not sufficiently powered to answer this question, so 
that the assumption that peptides with stronger HLA 
binding yield more IFNγ-producing T cells cannot be 
rejected. These data reflect a recent study on cytomegalo-
virus (CMV)- derived viral peptides in which also no clear 
correlation between HLA binding affinity and immuno-
genicity could be found. In this study, not all dominant 
CMV epitopes were contained within the 2% best binders 
and vice versa the group of strong binders harbored a 
high number of non- immunogenic peptides.65 There-
fore, the association between in silico HLA binding rank 
and immunogenicity remains elusive. Peripheral lympho-
cytes of AT/RT patients showed no memory responses 
against the identified class- I peptides, indicating that 
patients are indeed ‘CD8 naïve’ for all three types of 
HLA class I peptides investigated here. In this context, 
it would have been interesting to test reactivity of AT/
RT tumor- infiltrating lymphocytes (TILs); however, this 
was precluded by scarcity of the available tumor material. 
Notably, in melanoma non- canonical peptides were not 
recognized by CD8+ TILs.61 It is conceivable that due to 
their exceptional short half- life cryptic peptides are not 
presented to T cells via dendritic cells in lymphatic tissue, 
that is, that the peripheral T- cell repertoire of AT/RT 
patients is devoid of these specificities, but these could 
be de novo primed by therapeutic vaccines. In contrast 
to missing responses against class I peptides, ~83% of the 
tested HLA- II epitopes were recognized by patients’ Thelper 
cells. This can partly be explained by the higher promis-
cuity of class II ligands for HLA- II binding and presenta-
tion. Yet, this reactivity was tumor specific since PBMCs 
of high- grade glioma patients recognized only ~50% of 
the tested HLA- II epitopes at a lower level, whereas CD4 
T cells from healthy donors showed almost no reactivity. 
This indicates that the Thelper cell repertoire of AT/RT 
patients has been sensitized to tumor- associated class II 
epitopes during disease initiation. Furthermore, our data 
show a partial overlap of immunopeptidomes of two CNS 
tumors, GBM and AT/RTs on the level of natural and 
cryptic class I epitopes as well as by shared CD4+ recall 
responses. Eighteen per cent of the identified cryptic 
peptides were shared between AT/RTs and GBM, making 
these antigens highly promising candidates for future 
vaccines.
A limitation of our study certainly is that we worked 
predominantly with tumor banking material, which 
might have resulted in lower peptide yield due to subop-
timal quality of material. The scarcity of tumor material in 
these small children made it impossible to determine the 
reactivity of AT/RT TILs against the different peptides. 
Furthermore, the lack of clinical information to these 
samples precluded an analysis between immunological 
findings and clinical outcome.
In summary, AT/RTs as a paradigmatic example of a 
low- mutational pediatric cancer present a plethora of 
tumor- associated, immunogenic HLA class I and class 
II peptides. More than half of the class I peptides orig-
inated from non- canoncial translated proteins. Thus, 
personalized therapeutic vaccine cocktails should contain 
peptides from all three subgroups in order to have full 
representation of the entire tumor immunopeptidome in 
the vaccine. We could not identify entity- spanning HLA 
class I epitopes. However, our data show a broader overlap 
between different AT/RTs as well as with GBM samples in 
the cryptic class I and natural class II than in the natural 
class I ligandome. Therefore, in the quest for a broader 
applicable warehouse peptide pool, the former two ligan-
dome compartments should be further studied more in 
depth, whereas natural class I peptides will remain the 
domain of individualized peptide cocktails.
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